早期他汀类干预对不稳定性冠状动脉疾病患者血清C反应蛋白水平的影响  

Effect of early cholesterol-reducing on the serum level of high sensitive C-reactive protein in unstable coronary artery disease

作　　者：孙玉兰[1] 汤日波[3] 谢莲娜[1] 刘晓辉[1] 周洁[2] 

机构地区：[1]大连市友谊医院心内科,辽宁省大连116001 [2]大连市友谊医院检验科,辽宁省大连116001 [3]北京安贞医院心内科

出　　处：《中国基层医药》2007年第4期551-552,共2页Chinese Journal of Primary Medicine and Pharmacy

摘　　要：目的观察早期调脂干预对不稳定性冠状动脉疾病患者血清高敏C反应蛋白（hsCRP）的影响。方法50例连续入院的不稳定性冠状动脉疾病患者随机分为调脂治疗组和对照组,每组25例。治疗组在入院后予辛伐他汀20 mg夜间顿服,对照组未予调脂治疗。于入院时、入院后5 d（调脂治疗3 d）、12 d（调脂治疗10 d）测定血清hsCRP水平,并比较两组心绞痛发生次数及心绞痛累计时间。结果入院24 h、入院5 d和12 d治疗组hsCRP分别为（6．96±1．93）mg/L、（4．21±2．18）mg/L、（3．81±1．66）mg/L,组内比较差异有统计学意义（P＜0．05）;对照组分别为（7．44±6．52）mg/L、（5．32±3．48）mg/L、（4．98±1．74）mg/L,组内比较差异无统计学意义（P＞0．05）。入院时hsCRP两组间差异无统计学意义,入院12 d调脂治疗组hsCRP显著低于对照组（P＜0．05）。两组心绞痛次数及心绞痛累计时间差异无统计学意义。结论早期调脂干预可以降低不稳定性冠状动脉疾病急性期hsCRP水平。Objective To observe the effect of early cholesterol-reducing on the serum level of high sensitive C-reactive（hsCRP） in unstable coronary artery disease. Methods Fifty consecutive patients with unstable coronary artery disease were randomized into cholesterol-reducing group and control group （n = 25）. Cholesterol-reducing group were treated with simvastatin 20mg qn. hsCRP was assayed on the 1st, 5th and 12th day after admission. Angina frequency and cumulative angina time were documented. Results The serum level of hsCRP in the simvastatin group on the lst,5th and 12th day after admission was （6.96 ± 1.93）mg/L, （4.21 ± 2.18）mg/L, （3.81 ± 1.66）mg/L,respectively（P〈 0.05）,however it was （7.44±6.52） mg/L, （5.32 ± 3.48）mg/L, （4.98±1.74） mg/L respectively in the control group（P 〉 0.05）. The serum level of hsCRP in the simavastatin group on 12th day after admission was significantly lower than that in the control group（ P 〈 0.05）. There were no differences in angina frequency and cumulative angina time between the two groups. Conclusion Early cholesterol reducing can decrease hsCRP in unstable coronary artery disease.

关 键 词：冠状动脉疾病 炎性反应 他汀类药物 C反应蛋白 

分 类 号：R541[医药卫生—心血管疾病]